Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MFN2 | O95140 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL481973 | 1.00 | EPHX2 (0.68) | EPHX2POLBMMP2MMP8EPHX1 | |
| SCHEMBL1498319 | 1.00 | EPHX2 (0.68) | EPHX2POLBMMP2MMP8EPHX1 | |
| SCHEMBL14635075 | 0.91 | EPHX2 (0.58) | EPHX2POLBMMP2MMP8EPHX1 | |
| SCHEMBL14635074 | 0.91 | EPHX2 (0.58) | EPHX2POLBMMP2MMP8EPHX1 | |
| SCHEMBL14635076 | 0.91 | EPHX2 (0.58) | EPHX2POLBMMP2MMP8EPHX1 | |
| SCHEMBL6658887 | 0.89 | EPHX2 (0.50) | EPHX2POLBMMP2MMP8EPHX1 | |
| SCHEMBL245467 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL11416981 | 0.86 | — | — | |
| Pentane SCHEMBL15881674 | 0.85 | EPHX2 (0.52) | EPHX2EPHX1MAPTALDH1A1MEN1 | |
| SCHEMBL23548407 | 0.85 | EPHX2 (0.50) | EPHX2POLBMMP2MMP8EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 449 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3917509-A1 | TRANS-4-HYDROXYCYCLOHEXYL PHENYL AMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | Mitochondria Emotion, Inc. (US) | 2021-12-08 | — | — | EP | claimed |
| WO-2020159797-A1 | TRANS-4-HYDROXYCYCLOHEXYL PHENYL AMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MITOCHONDRIA EMOTION, INC. (US) | 2020-08-06 | — | — | WO | claimed |
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2015-01-22 | — | — | US | claimed |
| EP-2264030-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | Incyte Corporation (US) | 2010-12-22 | — | — | EP | claimed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | claimed |
| CN-1898234-A | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORP (US) | 2007-01-17 | — | — | CN | claimed |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | claimed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20240294506-A1 | CDK2 INHIBITORS | PFIZER INC. (US) | 2024-09-05 | — | — | US | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| US-12043612-B2 | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same | ARVINAS OPERATIONS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | LIFEARC (GB) | 2024-07-18 | — | — | US | disclosed |
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| WO-2004048352-A2 | 2-CYANOPYRROLIDINES AND THEIR ANALOGUES AS DPP-IV INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | WO | disclosed |
| CN-1501941-A | Chemical compounds | — | 2004-06-02 | — | — | CN | disclosed |
| CN-1147483-C | Adamantane derivative | — | 2004-04-28 | — | — | CN | disclosed |
| US-6492355-B1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
| CN-1353702-A | Adamantane derivative | ASTRAZENECA AB (SE) | 2002-06-12 | — | — | CN | disclosed |
| EP-1171432-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061569-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | DCK, ERCC2, POLK | EPHX2 3100/4885POLB 39/4885MMP2 1772/4885 |
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | EPHX2 3667/4885POLB 2451/4885MMP2 4345/4885 |
| US-12043612-B2 | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same | PAICS, UGT1A1, PBRM1 | EPHX2 1754/4885POLB 1359/4885MMP2 4075/4885 |
| US-20240294506-A1 | CDK2 INHIBITORS | CDK2, CDK1, CCNI | EPHX2 2617/4885POLB 634/4885MMP2 3283/4885 |
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP2, MMP14 | EPHX2 403/4885POLB 1479/4885MMP2 2/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | EPHX2 337/4885POLB 2157/4885MMP2 5/4885 |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | EPHX2 403/4885POLB 1479/4885MMP2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.